Blue Abstract Wave Banner

Key information

Chief Investigator: Gary Frost

ICTU Therapeutic area:  Other – opiate addiction 

ICTU collaboration: Operations; Statistics; Database

Email: iprevent@imperial.ac.uk

Study website: iPREVENT

Social media:

Trial registration:
ISRCTN16299902 

Status:  Close-out and analysIs

The iPREVENT trial is a randomised, placebo-controlled, double-blind trial to investigate the impact of inulin propionate ester (IPE) on weight gain prevention in adults aged 20 to 40 years at high risk of gaining weight. 270 participants have been randomised to either IPE or inulin control for 12 months. The iPREVENT trial is running at two UK sites; Imperial Clinical Research Facility (CRF) in London - Imperial College Healthcare NHS Trust and Glasgow CRF - NHS Research Scotland. 

iPREVENT videos

iPrevent Animation Play video

iPrevent Animation

iPrevent Animation

iPrevent Animation

iPrevent Animation long version

IPE - How It Works

IPE - How It Works

IPE - How It Works - Douglas Morrison

Therapeutic areas contacts

For contact details please visit Therapeutic areas contacts